A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-16

Study Completion Date

2023-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499. Which dose participant will get will be decided by chance. NNC0194-0499 is a medicine under clinical investigation. It means that the medicine has not yet been approved by the health authorities. Participant will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on stomach. The study will last for a maximum of 64 days. Participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of NST-6179 in Healthy Subjects

NCT05181085

Short Bowel Syndrome Parenteral Nutrition Associated Liver Disease

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

NCT03400995

Healthy

COMPLETED PHASE1

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

NCT05847439

Healthy Volunteers

COMPLETED PHASE1

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

NCT02541669

Healthy Volunteer

COMPLETED PHASE1

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

NCT02005744

Liver Dysfunction

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NNC0194-0499 12 mg

Participants will receive a single subcutaneous (s.c.) dose of 12 milligrams (mg) NNC0194-0499 on Day 1.

Group Type EXPERIMENTAL

NNC0194-0499

Intervention Type DRUG

Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.

NNC0194-0499 30 mg

Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

Group Type EXPERIMENTAL

NNC0194-0499

Intervention Type DRUG

Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

NNC0194-0499 96 mg

Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

Group Type EXPERIMENTAL

NC0194-0499

Intervention Type DRUG

Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NNC0194-0499

Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.

Intervention Type DRUG

NNC0194-0499

Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

Intervention Type DRUG

NC0194-0499

Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
* Chinese male aged 20-55 years (both inclusive) at the time of signing informed consent.
* Body mass index (BMI) between 23.0 and 34.9 kilograms per meter square (kg/m\^2) (both inclusive).
* Body weight greater than or equal to 60 kg.
* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria

* Known or suspected hypersensitivity to study intervention or related products.
* Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes